LIDDS

0.02 SEK

-29.65 %

Less than 1K followers

LIDDS

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-29.65 %

-45.00 %

-50.21 %

-59.26 %

-74.31 %

-82.65 %

-98.43 %

-99.82 %

-99.75 %

LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patented and clinically tested drug delivery technology. The properties of the products form the basis of the LIDDS technology platform for the development of injectable pharmaceutical products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System, and the company is headquartered in Uppsala.

Market cap

3.3M SEK

Turnover

22.54K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

19/2

2026

Annual report '25

28/5

2026

Interim report Q1'26

28/5

2026

General meeting '26

All

Press releases

ShowingAll content types

Regulatory press release2 hours ago

Kallelse till extra bolagsstämma, tillika andra kontrollstämma, i LIDDS AB (publ)

Regulatory press release2 hours ago

Notice of extraordinary general meeting, as well as the second control meeting, in LIDDS AB (publ)

Regulatory press release3 hours ago

LIDDS AB (publ) föreslår att bolagsstämman, tillika andra kontrollstämman, beslutar om frivillig likvidation och om avnotering av bolagets aktier

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release3 hours ago

LIDDS AB (publ) proposes that the general meeting, as well as the second control meeting, resolve on voluntary liquidation and the delisting of the company’s shares

Regulatory press release12/18/2025, 10:30 AM

Kommuniké från extra bolagsstämma i LIDDS AB (publ) den 18 december 2025

Regulatory press release12/18/2025, 10:30 AM

Announcement from extraordinary general meeting in LIDDS AB (publ) held on 18 December 2025

Regulatory press release12/10/2025, 6:00 PM

LIDDS AB (publ) har beslutat att avbryta processen avseende det omvända förvärvet av Proport Invest AB (publ)

Regulatory press release12/10/2025, 6:00 PM

LIDDS AB (publ) has decided to terminate the process regarding the reverse acquisition of Proport Invest AB (publ).

Regulatory press release12/1/2025, 4:15 PM

Byte av Certified Adviser (CA) till G&W Fondkommission

Regulatory press release12/1/2025, 4:15 PM

Change of Certified Adviser (CA) to G&W Fondkommission

Regulatory press release11/27/2025, 5:30 PM

LIDDS AB (publ) har ingått avtal om omvänt förvärv av Proport Invest AB (publ)

Regulatory press release11/27/2025, 5:30 PM

LIDDS AB (publ) has entered into an agreement for a reverse takeover of Proport Invest AB (publ)

Regulatory press release11/20/2025, 6:00 AM

LIDDS AB (publ) Delårsrapport januari – september 2025

Regulatory press release11/20/2025, 6:00 AM

LIDDS AB (publ) Interim Report January – September 2025

Regulatory press release11/13/2025, 8:20 PM

Kallelse till extra bolagsstämma i LIDDS AB (publ)

Regulatory press release11/13/2025, 8:20 PM

Notice of extraordinary general meeting in LIDDS AB (publ)

Press release11/13/2025, 8:10 PM

Styrelsen i LIDDS AB avser att föreslå minskning av bolagets aktiekapital för förlusttäckning

Press release11/13/2025, 8:10 PM

The board of directors of LIDDS AB intends to propose a reduction of the company’s share capital for loss coverage

Regulatory press release8/28/2025, 6:00 AM

LIDDS AB (publ) Delårsrapport januari – juni 2025

Regulatory press release8/28/2025, 6:00 AM

LIDDS AB (publ) Interim Report January – June 2025

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.